Related Experiment Video
Updated: Feb 16, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Treatment of ALK-positive nonsmall cell lung cancer: recent advances
Alesha A Thai1, Benjamin J Solomon1,2
1Department of Medical Oncology, Peter MacCallum Cancer Centre.
Purpose Of Review:
The review will highlight recent advances in development of ALK-TKIs and management of patients with ALK-positive nonsmall cell lung cancer.
Recent Findings:
There has been rapid progress in the use of targeted therapies for ALK-positive NSCLC. Since the discovery, development and approval of crizotinib in 2011, three second-generation ALK-TKIs, ceritinib, alectinib and brigatinib have been approved by the FDA. A range of newer generation ALK inhibitors with improved potency against ALK and against mutations that confer resistance to crizotinib are in clinical development.
Summary:
Our review will discuss the recent phase III data with ceritinib and alectinib as well as clinical trials with other ALK inhibitors. We will also address two important issues in the management of ALK-positive NSCLC, prevention and treatment of brain metastases and management of emergent ALK-TKI resistance mechanisms.
Insights
Recent advances in anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) offer new treatments for ALK-positive non-small cell lung cancer (NSCLC). This review covers new therapies and managing brain metastases and resistance.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK-positive NSCLC) is a distinct subtype.
- Targeted therapies, particularly ALK-tyrosine kinase inhibitors (TKIs), have revolutionized treatment.
- Crizotinib was the first ALK-TKI approved, followed by second-generation inhibitors like ceritinib, alectinib, and brigatinib.
Purpose of the Study:
- To highlight recent advancements in the development of ALK-TKIs.
- To discuss the current management strategies for patients with ALK-positive NSCLC.
- To review emerging challenges, including brain metastases and TKI resistance.
Main Methods:
- Comprehensive review of recent clinical trial data, focusing on Phase III studies.
- Analysis of data for approved and investigational ALK inhibitors.
- Discussion of strategies for managing specific clinical challenges in ALK-positive NSCLC.
Main Results:
- Several next-generation ALK inhibitors demonstrate improved potency and activity against resistance mutations.
- Newer ALK-TKIs show promising efficacy in clinical trials, expanding treatment options.
- Ongoing research addresses critical aspects like central nervous system (CNS) disease and acquired resistance.
Conclusions:
- The landscape of ALK-positive NSCLC treatment is rapidly evolving with novel TKI development.
- Effective management requires addressing brain metastases and overcoming resistance mechanisms.
- Continued research is crucial for optimizing patient outcomes with targeted therapies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...